@article {186,
	title = {A Novel Treatment for Type2 Diabetes Mellitus: Canagliflozin},
	journal = {International Journal of Pharmacology and Clinical Sciences},
	volume = {2},
	year = {2013},
	month = {December 2013},
	pages = {129-134},
	type = {New Drug Information},
	chapter = {129},
	abstract = {<p class="rtejustify">Sodium glucose co-transporter type 2 (SGLT2) inhibitors, as a new class for treatment of Type 2 diabetes mellitus, offer a novel mechanism of action, and are very effective in bringing the blood sugar levels down, either alone or in combination with other oral hypoglycaemic agents, with minimal side effects. Among the several drugs in this group, which are in various stages of clinical trials, canagliflozin has been recently approved by USFDA for use in type 2 dia-betes mellitus, either alone or in combination with other oral hypoglycaemic agents and insulin.</p>
},
	keywords = {Blood glucose, Canagliflozin, SGLT2 inhibitors},
	author = {Sangeeta Bhanwra and Kaza Ahluwalia}
}
